US Government collaboration for Galidesivir development
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Island Pharmaceuticals Ltd has announced a Cooperative Research and Development Agreement with the US Army Medical Research Institute of Infectious Diseases and The Geneva Foundation to advance the development of Galidesivir for treating Marburg Virus Disease. This collaboration aims to accelerate the drug's approval process under the FDA's Animal Rule development pathway, leveraging previous successful studies with non-human primates.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Island Pharmaceuticals Ltd on 6ix
Story so far
Earlier from Island Pharmaceuticals
- Trading Halt
- Appendix 4D & Half-Year Financial Statements
- Response to ASX Query Letter
- $9m placement to advance US biodefence opportunity
- FDA confirms Galidesivir approval pathway
Later from Island Pharmaceuticals
- Antiviral pipeline expansion through strategic collaboration
- Island Bolsters US Biodefence Readiness Ahead of Trials
- Island Adds Biodefence Leader as Filovirus Risks Escalate
- Island Advances Galidesivir GMP Manufacturing for Biodefence
- Island Secures USAMRIID Support for Galidesivir Study
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals